Key Messages
COVID-19 PNEUMONIA
In our small single-site, randomized, double-blind, placebo-controlled clinical trial that enrolled 32 participants, anakinra added to dexamethasone did not significantly impact survival in COVID-19 pneumonia CSS patients;The serum levels of IL-6 were significantly higher in patients who did not survive compared to patients who did survive;The treatment with anakinra was associated with decreases in CXCL9 levels;Additional studies are needed to assess the efficacy, timing, dosing, and duration of anakinra treatment in select COVID-19 CSS patients.